Deirdre B. Rogers, MS Director Mississippi Cancer Registry

1
Mississippi Cancer Registry

• Deirdre B. Rogers, MS
• Director
• Mississippi Cancer Registry

2
MCR Staff

• Debra Christie, MBA, RHIA, CTR, CCRP
• Director, Cancer Research and Registry
• Deirdre Rogers, MS
• Director, Mississippi Cancer Registry
• Kathryn Sheppard, RHIA, CTR
• Cancer Registry Coordinator
• Donna Gooch
• Cancer Registry Coordinator

3
MCR Staff

• LaTawnya Roby
• Cancer Registry Coordinator
• Carla Triplett, RHIT
• Cancer Registry Coordinator
• Kristy Brister, RHIA
• Cancer Registry Coordinator
• Ramona Corkern, RHIA, CCS
• HIM Systems Analyst

4
MCR History

• 1993 - Mississippi Legislature authorized
  Mississippi State Department of Health to
  establish a central population-based incidence
  cancer registry
• Data collection began January 1996
• 2004 Program was relocated to the University of
  Mississippi Medical Center

5
Reporting Cases

• Report cases monthly
• If you upload your file, please zip the file
  before uploading
• If you enter data directly into HRN and your
  patient information is automatically filled in
  for you, please mark the check box next to
  Reconcile Hold.
• Send corrections on paper. Write Correction at
  the top and highlight the corrected item(s). Do
  not resend the case electronically

6
Reportable Cases

• Refer to your list of reportable cases.
• Cases diagnosed on or after January 1, 1996
• Diagnosed and/or treated at your facility
• Pathology only cases read by pathologists must be
  reported (i.e., interpretation for another
  facility sent for a second opinion procedure
  elsewhere sent to pathology).

7

• Physician cases
• VAIN III, VIN III, AIN III (Not required by ACoS
  Required by NPCR/MCR)
• Benign and borderline brain tumors (Behavior
  codes 0 1) effective January 1, 2004
• Be sure to refer to the list of ambiguous terms
  when determining if reportable.

8
Do Not Report

• History only of cancer cases
• Basal cell and squamous cell carcinomas of the
  skin
• PIN III
• CIN III
• CIS of cervix

9
Flow of Data through the MCR

• Data Reported by the Facilities
• Hospitals with software Upload into HRN
• Facilities with gt25 cases and no software Enter
  directly into HRN
• Facilities with lt25 cases Paper abstracts
  entered into HRN by MCR staff
• Data is matched within the system. Multiple
  reports for a cancer are consolidated.
• Quality Control is performed on data.

10
Flow of Data through the MCR

• Follow-back is conducted on all pathology-only
  (class 7) cases.
• Interstate data exchange is conducted biennially.
• All data matched with the mortality data from
  MSDH Vital Records.
• Vital status, cause of death and date of death
  recorded.
• Follow-up conducted on all cancer deaths with no
  matching incidence record.

11
Flow of Data through the MCR

• Data is submitted to the CDCs National Program
  of Cancer Registries in January of each year.
• Data is analyzed and published.

12
Other MCR Activities

• Training and Technical Assistance
• Audits

13
Importance of Text

• Text is the most important part of the record for
  the MCR
• We all make mistakes. Text helps correct the
  mistakes.
• Record consolidation can be impossible without
  text.
• The MCR cannot access the medical records, so we
  use the text fields in place of a medical record.

14
Physical Exam

• Age, sex, race/ethnicity
• Past medical/social history
• Symptoms
• Tumor location and size
• Palpable lymph nodes
• Impression (when stated and pertains to cancer
  diagnosis)

15
Laboratory

• Type of lab test/tissue specimen(s)
• Record both positive and negative findings
  positive first
• Serum and urine electrophoresis, special studies,
  etc.
• Tumor markers

16
Pathology

• Date(s) of procedure(s)
• Pathology report number
• Type of tissue specimen(s)
• Tumor type and grade (site and histology)
• Gross tumor size
• Extent of tumor spread
• Involvement of surgical margins
• Number of lymph nodes involved and/or examined
• Note if path report is a slide review or second
  opinion
• Record any additional comments from the
  pathologist, including differential diagnoses
  considered and any ruled out or favored.

17
Scopes, X-rays, and Scans

• Date of procedure
• Tumor location
• Tumor size
• Types of lymph nodes, if given number of lymph
  nodes involved and examined
• Distant disease or metastasis

18
Operations

• Dates and descriptions of biopsies and all other
  surgical procedures from which staging
  information was derived.
• Number of lymph nodes removed and/or examined
• Size of tumor removed
• Documentation of residual tumor
• Evidence of invasion of surrounding area.

19
Staging

• Organs involved by direct extension
• Size of tumor
• Status of margins
• Number and sites of positive lymph nodes
• Site(s) of distant metastasis

20
Place of Diagnosis

• Fill in the name of the facility where the
  patient was diagnosed.
• If your facility diagnosed the patient, then put
  your facilitys name in this field.

21
Primary Site Title and Morphology Title

• Please do not skip these fields
• Be specific
• Example
• Primary Site Title Rt Lower Lobe Lung
• Morphology Title Squamous Cell
  Carcinoma

22
Remarks

• Document any information that would be beneficial
• Names and contact information of other treating
  physicians or healthcare facilities
• Additional information not stated in the other
  text fields

23
Surgery, Radiation, Chemotherapy, Hormone, BRM,
or Other Therapy

• Treatment date(s)
• Where treatment was given
• Type of treatment
• Other text, such as, patient discontinued after
  five cycles or unknown if therapy given

24
And Finally

• Avoid Unknowns (i.e., summary stage, birth date,
  race, etc.)
• If you need help, please contact the MCR at
  601-815-5482.